Kalaris reports positive Phase 1a results for TH103 in neovascular AMD
Kalaris Therapeutics reported extended retention and vision improvements in Phase 1a TH103 trials for neovascular AMD. The delayed time to retreatment suggests potential differentiation against existing anti-VEGF therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day